Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging (CVMRI)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Michael Buonocore, MD, PhD, University of California, Davis Identifier:
First received: January 3, 2008
Last updated: October 30, 2012
Last verified: October 2012

This Protocol is intended to facilitate development and testing of new cardiovascular MRI software capabilities by UC Davis Research Faculty, as well as to facilitate the evaluation of new software capabilities provided by GE and Siemens.

Abnormalities, Cardiovascular

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging

Resource links provided by NLM:

Further study details as provided by University of California, Davis:

Primary Outcome Measures:
  • Extend or generalize certain capabilities, such as new data acquisition pulse sequences, new image processing and analysis software for structural and functional analysis of the MR images [ Time Frame: Post-scanning ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improve image quality by various techniques (e.g. reducing the effects of motion) [ Time Frame: Post-scanning ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: May 1999
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Detailed Description:

This protocol will permit normal subjects, as well as patients with suspected or proven medical conditions, to undergo MRI studies using the new software capabilities. This Protocol is not restricted to imaging of a particular organ system or disease. The Protocol does not involve injection of any contrast agent, or other minimally-invasive or invasive procedure. It is intended only for those cases for which the only requirement of the subject is to relax and lie still while imaging is being performed.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Noraml volunteers and patients with known or suspected cardiovascular disease


Inclusion Criteria:

  • 18 years of age or older
  • Ability to give informed, written consent
  • Not Pregnant or breastfeeding

Exclusion Criteria:

  • Electrically, magnetically, or mechanically activated implants (for example, cardiac-pacemakers)
  • Ferromagnetic implant, such as an aneurysm clip, surgical clip, or prosthesis
  • History of uncontrolled claustrophobia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00593541

Sponsors and Collaborators
Michael Buonocore, MD, PhD
Principal Investigator: Michael H Buonocore, MD, PhD University of California, Davis
  More Information

No publications provided

Responsible Party: Michael Buonocore, MD, PhD, Principal Investigator, University of California, Davis Identifier: NCT00593541     History of Changes
Other Study ID Numbers: 200210689
Study First Received: January 3, 2008
Last Updated: October 30, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Davis:

Additional relevant MeSH terms:
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities processed this record on November 25, 2014